Is GSK prepping a $1bn takeover bid for IDRx? | pharmaphorum
1 day ago · GSK is reportedly in late-stage negotiations about a $1 billion deal to acquire IDRx and its experimental targeted therapy for a form of rare gastrointestinal stromal tumour (GIST). The rumoured ...
Press release archive - GSK
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK's Shingrix New Prefilled Syringe Presentation Accepted For …
5 hours ago · (RTTNews) - British drug maker GSK plc (GSK, GSK.L) announced Friday that the US Food and Drug Administration has accepted for review the regulatory application of a prefilled syringe presentation ...
GSK in Talks to Buy U.S. Rare Tumor Specialist IDRx for up to $1 ...
1 day ago · --Pharmaceutical giant GSK PLC is in talks to buy U.S. privately owned biotech company IDRx, which is developing a treatment for rare gastrointestinal tumors, for up to $1 billion, the Financial ...
Next stage in GSK’s Zantac defense gets underway today
2 days ago · A hearing will get underway in Delaware later today in the latest phase of GSK’s attempts to defend itself from allegations that its Zantac drug caused cancer in patients.
GSK nears $1bn deal for biotech developing drug for rare tumour
1 day ago · GSK nears $1bn deal for biotech developing drug for rare tumour ... Share News Tips Securely Individual Subscriptions Professional Subscriptions Republishing Executive Job Search Advertise with ...
FDA Grants Breakthrough Therapy Designation For GSK's GSK'227 …
3 days ago · (RTTNews) - GSK plc (GSK), a pharmaceutical and biotechnology company, on Tuesday announced that the U.S. Food and Drug Administration or FDA has granted Breakthrough Therapy Designation for GSK ...
Press releases | GSK US
GSK is outfitting its Marietta, Pennsylvania, site with new state-of-the-art facilities dedicated to producing medicines and vaccines. Single dose of vaccine elicited robust immune response with acceptable safety profile in adults aged 18-49 at increased risk for RSV-LRTD. Studies from OPERA and Trio cohorts provide further real-world evidence.
GSK makes a strong start to 2024 with improving outlook for the …
May 1, 2024 · "We have made a strong start to 2024, with another quarter of excellent performance and continued pipeline progress, including positive data read outs for 4 phase III medicines.
GSK delivers continued strong performance and upgrades 2024 …
Jul 31, 2024 · "GSK's momentum this year continues with excellent second quarter performance, reflecting strong operational execution and the strengthening breadth of our portfolio to both prevent and treat disease.